Lv4
458 积分 2022-08-02 加入
Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial
2个月前
已完结
An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low)
5个月前
已完结
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
5个月前
已完结
460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers
6个月前
已关闭
ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers
6个月前
已完结
Upregulation of vesicle-associated membrane protein 7 in breast cancer tissues
6个月前
已完结
Preferential overexpression of glutaredoxin3 in human colon and lung carcinoma
6个月前
已完结
IRF4 as a molecular biomarker in pan-cancer through multiple omics integrative analysis
6个月前
已关闭
皖公网安备34019202002308
